ArticleFrontiers in immunology2026
An advanced, highly sensitive and versatile
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Evaluating next-generation prophylactic human papillomavirus (HPV) vaccines requires high-throughput and scalable neutralization assays spanning a wide array of genotypes. Standard secreted alkaline phosphatase (SEAP)-based platforms, however, are limited by tedious protocols, such as mandatory serum heat inactivation, and restricted sensitivity. To address these bottlenecks, we developed an advanced pseudovirus (PsV) platform using Cypridina luciferase (cLuc), a versatile dual-reporter system that facilitates both extracellular secretion and intracellular monitoring. Methods: A comprehensive library of cLuc-engineered PsVs was constructed, covering 28 distinct mucosal and cutaneous HPV genotypes. We verified their structural integrity and antigenic presentation via neutralization profiling with L2 N-terminus-specific monoclonal antibodies (JWW-1/JWW-2). Results: The cLuc-PsVs demonstrated robust infectivity along with excellent analytical linearity. Critically, this system eliminated the need for thermal inactivation of sera while maintaining an exceptional correlation (R² > 0.99) with traditional SEAP assays during evaluations of hyperimmune mouse sera. Beyond in vitro screens, the platform's translational value was confirmed in a murine cervicovaginal challenge model, where real-time bioluminescence imaging enabled non-invasive tracking of mucosal infection across all 28 genotypes. Discussion: This dual-purpose cLuc-PsV platform provides a highly efficient, sensitive alternative to conventional neutralization assays. By unifying high-throughput in vitro quantification with longitudinal in vivo imaging, this system offers a robust tool to accelerate the preclinical screening of multivalent HPV vaccine candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.